Danimer Scientific Names Richard Altice Interim CEO; Preliminary Q3 PHA Revenue Of $6.7M Increased By $0.8M Compared To Q2 2024; Company Maintains Its Forecast That Annualized PHA Revenues Will More Than Triple By The End Of Q2 2025
Portfolio Pulse from Benzinga Newsdesk
Danimer Scientific appoints Richard Altice as Interim CEO and reports a preliminary Q3 2024 PHA revenue increase to $6.7M. The company forecasts annualized PHA revenues to more than triple by Q2 2025.
October 15, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Danimer Scientific has appointed Richard Altice as Interim CEO, succeeding Stephen Croskrey. The company reported a preliminary Q3 2024 PHA revenue of $6.7M, an increase from Q2 2024. Danimer maintains its forecast for PHA revenues to more than triple by Q2 2025.
The appointment of a new interim CEO and the increase in PHA revenue are positive indicators for Danimer Scientific. The company's forecast for significant revenue growth by Q2 2025 suggests strong future performance, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100